ReviewJournal of advanced research2026
Gut microbiota: A key player for soluble dietary fiber in regulating inflammatory disease.
Review in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Oral‑gut axis in systemic disease: A barrier‑metabolism‑immunity three‑dimensional regulatory model (Review).International journal of molecular medicine · 2026Review
- Psyllium and Glucomannan as Viscous Fiber Modulators of the Gut-Microbiome-Incretin Axis: Molecular Links to Metabolic Inflammation, Barrier Function, and GLP-1 Receptor Agonist Therapy.International journal of molecular sciences · 2026Review
- The Oral-Gut-Immune-Nutrition Axis in Rheumatoid Arthritis: Molecular Mechanisms and Therapeutic Implications.International journal of molecular sciences · 2026Review
- Inflammatory bowel diseases: pathological mechanisms and therapeutic perspectives.Molecular biomedicine · 2026Review
- Nutrition in the prevention and treatment of pelvic inflammatory disease: a review.Frontiers in nutrition · 2026Review
- From pathogenic mechanisms to therapeutic perspectives: a review of gut microbiota and intestinal mucosal immunity in inflammatory bowel disease.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Soluble dietary fiber (SDF) plays a significant role in modulating immune responses, particularly in the context of inflammatory diseases. SDF enhances intestinal barrier integrity and regulates immune function by modulating the composition of the gut microbiota and increasing the production of beneficial microbial metabolites, such as short-chain fatty acids (SCFAs), 3-hydroxyoctadecaenoic acid, pentadecanoic acid, and bile acids. Current evidence suggests that SDF holds therapeutic potential in managing chronic inflammatory diseases such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and metabolic dysfunction-associated steatohepatitis (MASH). Despite these promising findings, the mechanisms by which SDF exerts its effects, particularly in distal organs and neuroinflammatory conditions, remain poorly understood. This review explores the mechanistic pathways by which SDF modulates immune regulation and highlights the current challenges and future strategies for optimizing its clinical application in treating inflammatory diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.